Premium
Paroxetine in the treatment of depression: a comparison with imipramine and placebo
Author(s) -
Feighner J.P.,
Boyer W.F.
Publication year - 1989
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1989.tb07190.x
Subject(s) - paroxetine , imipramine , hamd , placebo , antidepressant , depression (economics) , psychology , reuptake inhibitor , psychiatry , medicine , anesthesia , pharmacology , anxiety , alternative medicine , macroeconomics , pathology , economics
ABSTRACT Paroxetine is a selective serotonin uptake inhibitor, which is being investigated as an antidepressant. In this double‐blind, six‐week study 120 outpatients with DSM‐I11 major depression were randomly assigned to treatment with paroxetine, imipramine, or placebo. Results showed a statistically significant superiority of paroxetineover placebo on almost all outcome measures. Paroxetine was significantly superior to imipramine on the HAMD total score and was generally better tolerated than imipramine. The results support paroxetine's effectiveness in the treatment of major depression and suggest that further studies with this compound are warranted.